About this document

Development of Anti-CD32b Antibodies by 216829 is a document available to read on EtoBox.

The document discusses the development of two anti-CD32b monoclonal antibodies, NVS32b1 and NVS32b2, aimed at treating B and plasma cell malignancies, particularly in patients with chronic lymphocytic leukemia and multiple myeloma. These antibodies are designed to enhance immune responses against CD32b-expressing malignant cells by blocking CD32b-mediated resistance to existing therapies and promoting antibody-dependent cellular cytotoxicity and phagocytosis. The findings suggest that these antibodies could

Author

216829

Language

EN